{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:22Z","timestamp":1792784842901,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472771"],"award-info":[{"award-number":["82472771"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273139"],"award-info":[{"award-number":["82273139"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303043"],"award-info":[{"award-number":["82303043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470821"],"award-info":[{"award-number":["32470821"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272679"],"award-info":[{"award-number":["82272679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Eastern Talent Plan - Youth Project"},{"name":"Shanghai Municipal Health Commission, Clinical Research Special Project for Young Scholars"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,2,3]]},"DOI":"10.1038\/s41388-025-03660-1","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:36:20Z","timestamp":1765899380000},"page":"431-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis"],"prefix":"10.1038","volume":"45","author":[{"given":"Jizhuang","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiman","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5002-2535","authenticated-orcid":false,"given":"Yajuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-193X","authenticated-orcid":false,"given":"Lifang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"3660_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135:584\u201390.","journal-title":"Chin Med J"},{"key":"3660_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/07357907.2022.2119479","volume":"41","author":"F Abu Rous","year":"2022","unstructured":"Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A. Lung cancer treatment advances in 2022. Cancer Investig. 2022;41:12\u201324.","journal-title":"Cancer Investig"},{"key":"3660_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2021","unstructured":"Melosky B, Kambartel K, H\u00e4ntschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagnosis Ther. 2021;26:7\u201318.","journal-title":"Mol Diagnosis Ther"},{"key":"3660_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer. N Engl J Med. 2017;376:629\u201340.","journal-title":"N Engl J Med"},{"key":"3660_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389:137\u201347.","journal-title":"N Engl J Med"},{"key":"3660_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391:585\u201397.","journal-title":"N Engl J Med"},{"key":"3660_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41419-022-05050-x","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Wang SQ, Wang L, Lin H, Zhu JB, Chen R, et al. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression. Cell Death Dis. 2022;13:657.","journal-title":"Cell Death Dis"},{"key":"3660_CR8","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-22-3059","volume":"83","author":"Z Lin","year":"2023","unstructured":"Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X, et al. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitorsin non-small cell lung cancer. Cancer Res. 2023;83:2187\u2013207.","journal-title":"Cancer Res"},{"key":"3660_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03382-6","volume":"24","author":"W Fan","year":"2024","unstructured":"Fan W, Xing Y, Yan S, Liu W, Ning J, Tian F, et al. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-\u03b2\/Smad signaling pathway in lung adenocarcinoma. Cancer Cell Int. 2024;24:208.","journal-title":"Cancer Cell Int"},{"key":"3660_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41397-019-0110-4","volume":"20","author":"Q Meng","year":"2019","unstructured":"Meng Q, Wang S, Zhou S, Liu H, Ma X, Zhou X, et al. Dissecting the m6A methylation affection on afatinib resistance in non-small cell lung cancer. Pharmacogenomics J. 2019;20:227\u201334.","journal-title":"Pharmacogenomics J"},{"key":"3660_CR11","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.3390\/cancers14225582","volume":"14","author":"Y Ji","year":"2022","unstructured":"Ji Y, Zhao Q, Feng W, Peng Y, Hu B, Chen Q. N6-methyladenosine modification of CIRCKRT17 initiated by METTL3 promotes osimertinib resistance of lung adenocarcinoma by EIF4A3 to enhance YAP1 stability. Cancers. 2022;14:5582.","journal-title":"Cancers"},{"key":"3660_CR12","unstructured":"Fan S, Lv X, Zhang C, Zeng B, Liang Y, Chen D, et al. METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells. Mol Cancer Res. 2024: OF1-OF13."},{"key":"3660_CR13","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254\u201361.","journal-title":"Science"},{"key":"3660_CR14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41388-024-02992-8","volume":"43","author":"X Xu","year":"2024","unstructured":"Xu X, Qiu S, Zeng B, Huang Y, Wang X, Li F, et al. N6-methyladenosine demethyltransferase FTO mediated m6A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis. Oncogene. 2024;43:1288\u2013302.","journal-title":"Oncogene"},{"key":"3660_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101801","volume":"38","author":"L Ma","year":"2021","unstructured":"Ma L, Chen T, Zhang X, Miao Y, Tian X, Yu K, et al. The m6A reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11-dependent antioxidant function. Redox Biol. 2021;38:101801.","journal-title":"Redox Biol"},{"key":"3660_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101576","volume":"5","author":"X Chen","year":"2024","unstructured":"Chen X, Cheng G, Zhu L, Liu T, Yang X, Liu R, et al. Alarmin S100A8 imparts chemoresistance of esophageal cancer by reprogramming cancer-associated fibroblasts. Cell Rep Med. 2024;5:101576.","journal-title":"Cell Rep Med"},{"key":"3660_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.715","volume":"5","author":"Y Qu","year":"2024","unstructured":"Qu Y, Gao N, Zhang S, Gao L, He B, Wang C, et al. Role of N6-methyladenosine RNA modification in cancer. MedComm. 2024;5:e715.","journal-title":"MedComm"},{"key":"3660_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/cr.2017.99","volume":"27","author":"PJ Hsu","year":"2017","unstructured":"Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, et al. Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27:1115\u201327.","journal-title":"Cell Res"},{"key":"3660_CR19","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.7150\/ijbs.58514","volume":"17","author":"J Wang","year":"2021","unstructured":"Wang J, Tan L, Jia B, Yu X, Yao R, Ouyang N, et al. Downregulation of m6A reader YTHDC2 promotes the proliferation and migration of malignant lung cells via CYLD\/NF-\u03baB Pathway. Int J Biol Sci. 2021;17:2633\u201351.","journal-title":"Int J Biol Sci"},{"key":"3660_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"3660_CR21","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26:2654\u201363.","journal-title":"Clin Cancer Res"},{"key":"3660_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s12033-023-01002-8","volume":"66","author":"Y Sun","year":"2023","unstructured":"Sun Y, Liu Y, Wang P, Chang L, Huang J. The m6A reader YTHDC2 suppresses lung adenocarcinoma tumorigenesis by destabilizing MRPL12. Mol Biotechnol. 2023;66:1051\u201361.","journal-title":"Mol Biotechnol"},{"key":"3660_CR23","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/0008-5472.CAN-22-2449","volume":"83","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhou J, Li J, Wang Z, Chen Z, Lv Z, et al. N6-methyladenosine promotes translation of VEGFA to accelerate angiogenesis in lung cancer. Cancer Res. 2023;83:2208\u201325.","journal-title":"Cancer Res"},{"key":"3660_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.freeradbiomed.2021.03.023","volume":"168","author":"L Ma","year":"2021","unstructured":"Ma L, Zhang X, Yu K, Xu X, Chen T, Shi Y, et al. Targeting SLC3A2 subunit of system XC- is essential for m6A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma. Free Radic Biol Med. 2021;168:25\u201343.","journal-title":"Free Radic Biol Med"},{"key":"3660_CR25","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1002\/iub.2341","volume":"72","author":"Y Li","year":"2020","unstructured":"Li Y. Copper homeostasis: emerging target for cancer treatment. IUBMB Life. 2020;72:1900\u20138.","journal-title":"IUBMB Life"},{"key":"3660_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.110943","volume":"393","author":"Z Qiu","year":"2024","unstructured":"Qiu Z, Liu Q, Wang L, Xiong Y, Wu J, Wang M, et al. The copper transporter, SLC31A1, transcriptionally activated by ELF3, imbalances copper homeostasis to exacerbate cisplatin-induced acute kidney injury through mitochondrial dysfunction. Chem-Biol Interact. 2024;393:110943.","journal-title":"Chem-Biol Interact"},{"key":"3660_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-023-01489-9","volume":"16","author":"F-S Kong","year":"2023","unstructured":"Kong F-S, Ren C-Y, Jia R, Zhou Y, Chen J-H, Ma Y. Systematic pan-cancer analysis identifies SLC31A1 as a biomarker in multiple tumor types. BMC Med Genomics. 2023;16:61.","journal-title":"BMC Med Genomics"},{"key":"3660_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12568","volume":"52","author":"Z Yu","year":"2019","unstructured":"Yu Z, Zhou R, Zhao Y, Pan Y, Liang H, Zhang JS, et al. Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death. Cell Prolif. 2019;52:e12568.","journal-title":"Cell Prolif"},{"key":"3660_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103558","volume":"71","author":"G Wu","year":"2021","unstructured":"Wu G, Peng H, Tang M, Yang M, Wang J, Hu Y, et al. ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. eBioMedicine. 2021;71:103558.","journal-title":"eBioMedicine"},{"key":"3660_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121335","volume":"281","author":"Y Lu","year":"2022","unstructured":"Lu Y, Pan Q, Gao W, Pu Y, Luo K, He B, et al. Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens. Biomaterials. 2022;281:121335.","journal-title":"Biomaterials"},{"key":"3660_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.752825","volume":"12","author":"Y Hu","year":"2021","unstructured":"Hu Y, Qian Y, Wei J, Jin T, Kong X, Cao H, et al. The disulfiram\/copper complex induces autophagic cell death in colorectal cancer by targeting ULK1. Front Pharmacol. 2021;12:752825.","journal-title":"Front Pharmacol"},{"key":"3660_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2015.07.029","volume":"369","author":"Y Li","year":"2015","unstructured":"Li Y, Fu S-Y, Wang L-H, Wang F-Y, Wang N-N, Cao Q, et al. Copper improves the anti-angiogenic activity of disulfiram through the EGFR\/Src\/VEGF pathway in gliomas. Cancer Lett. 2015;369:86\u201396.","journal-title":"Cancer Lett"},{"key":"3660_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176110","volume":"960","author":"X Ni","year":"2023","unstructured":"Ni X, Ye C, Yu X, Zhang Y, Hou Y, Zheng Q, et al. Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram\/copper-induced oxidative stress and ferroptosis in renal cell carcinoma. Eur J Pharmacol. 2023;960:176110.","journal-title":"Eur J Pharmacol"},{"key":"3660_CR34","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41416-019-0609-0","volume":"121","author":"Y Kita","year":"2019","unstructured":"Kita Y, Hamada A, Saito R, Teramoto Y, Tanaka R, Takano K, et al. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. Br J Cancer. 2019;121:1027\u201338.","journal-title":"Br J Cancer"},{"key":"3660_CR35","doi-asserted-by":"publisher","first-page":"113465","DOI":"10.1016\/j.biopha.2022.113465","volume":"153","author":"M Hendrych","year":"2022","unstructured":"Hendrych M, \u0158\u00edhov\u00e1 K, Adamov\u00e1 B, Hradil V, Stiborek M, Vl\u010dek P, et al. Disulfiram increases the efficacy of 5-fluorouracil in organotypic cultures of colorectal carcinoma. Biomed Pharmacother. 2022;153:113465.","journal-title":"Biomed Pharmacother"},{"key":"3660_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3892\/ijmm.2023.5343","volume":"53","author":"P Li","year":"2023","unstructured":"Li P, Sun Q, Bai S, Wang H, Zhao L. Combination of the cuproptosis inducer disulfiram and anti\u2011PD\u2011L1 abolishes NSCLC resistance by ATP7B to regulate the HIF\u20111 signaling pathway. Int J Mol Med. 2023;53:19.","journal-title":"Int J Mol Med"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03660-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03660-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03660-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:03:00Z","timestamp":1768258980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03660-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,3]]}},"alternative-id":["3660"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03660-1","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}